Lucigen Gets $226K SBIR Grant from NIH

As part of the SBIR Phase I grant, Lucigen will develop genomic tools that can be used to discover and characterize new therapeutics agents from fungi.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories